Enanta Pharmaceuticals Inc

9EP

Company Profile

  • Business description

    Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

  • Contact

    4 Kingsbury Avenue
    WatertownMA02472
    USA

    T: +1 617 607-0800

    E: [email protected]

    https://www.enanta.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2026

    Employees

    131

Stocks News & Analysis

stocks

Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%

We see faster cloud growth and improved longer-term profitability for Alphabet.
stocks

Overvalued ASX mining giant

Solid start to 2026 but shares overvalued.
stocks

Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?

With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,317.2026.50-0.28%
CAC 408,225.630.15-0.00%
DAX 4024,239.8932.100.13%
Dow JONES (US)47,207.12472.511.01%
FTSE 1009,645.6267.050.70%
HKSE26,160.15192.170.74%
NASDAQ23,204.87263.071.15%
Nikkei 22549,299.65658.041.35%
NZX 50 Index13,391.5914.490.11%
S&P 5006,791.6953.250.79%
S&P/ASX 2009,019.0025.20-0.28%
SSE Composite Index3,950.3127.900.71%

Market Movers